This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Cytokinetics (CYTK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -28.43% and 98.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday
by Zacks Equity Research
Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding.
Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -14.66% and 26.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Omega Therapeutics, Inc. (OMGA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omega Therapeutics (OMGA) delivered earnings and revenue surprises of 5.26% and 155.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 10% and 102.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Vanguard S&P Small-Cap 600 ETF (VIOO) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VIOO
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -33.98% and 82.48%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last?
by Zacks Equity Research
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Novartis' (NVS) Strong Portfolio, Pipeline to Fuel Growth in 2024
by Zacks Equity Research
Novartis (NVS) is poised to outperform in 2024, backed by a diverse portfolio and a deep pipeline.
Cytokinetics (CYTK) Down on Report of Novartis Not Interested
by Zacks Equity Research
Cytokinetics (CYTK) slumps after a report stating Novartis not interested in acquiring the company surface.
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
by Zacks Equity Research
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
Cytokinetics (CYTK) Up 83% as Cardiomyopathy Drug Meets Goals
by Zacks Equity Research
Cytokinetics (CYTK) reports positive results from its pivotal late-stage study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy patients. The stock rallies 83% in response.
Biotech Stock Roundup: BMY's KRTX and RYZB Acquisition, CYTK Surges on Study Data
by Ekta Bagri
Bristol Myers (BMY) and Cytokinetics (CYTK) are in the news on acquisition announcements and study updates, respectively.
Company News for Dec 28, 2023
by Zacks Equity Research
Companies In The Article Are:CYTK,TSLA, NYT, MSFT, IOVA
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -87.50% and 98.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Believe Cytokinetics (CYTK) Could Rally 75.5%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Cytokinetics (CYTK) points to a 75.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Merck (MRK) Inks Deal With Daiichi to Develop Cancer Drugs
by Zacks Equity Research
Per the terms, Merck (MRK) and Daiichi Sankyo will develop and market three ADC drugs to treat multiple types of cancer. Following the execution, Merck will make an upfront payment of $4 billion.
Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -8.94% and 65.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 0% and 7.57%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -11.29% and 163.60%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline
by Zacks Equity Research
Urogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.